SG169383A1 - Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products - Google Patents

Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products

Info

Publication number
SG169383A1
SG169383A1 SG201100806-7A SG2011008067A SG169383A1 SG 169383 A1 SG169383 A1 SG 169383A1 SG 2011008067 A SG2011008067 A SG 2011008067A SG 169383 A1 SG169383 A1 SG 169383A1
Authority
SG
Singapore
Prior art keywords
monoclonal antibody
tumors
vectors
treatment
fragments
Prior art date
Application number
SG201100806-7A
Other languages
English (en)
Inventor
Paolo Maria Comoglio
Elisa Vigna
Silvia Giordano
Original Assignee
Metheresis Translational Res S A Ch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metheresis Translational Res S A Ch filed Critical Metheresis Translational Res S A Ch
Publication of SG169383A1 publication Critical patent/SG169383A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG201100806-7A 2006-02-06 2007-02-05 Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products SG169383A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06101345 2006-02-06

Publications (1)

Publication Number Publication Date
SG169383A1 true SG169383A1 (en) 2011-03-30

Family

ID=36616994

Family Applications (2)

Application Number Title Priority Date Filing Date
SG201100806-7A SG169383A1 (en) 2006-02-06 2007-02-05 Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
SG201100805-9A SG169382A1 (en) 2006-02-06 2007-02-05 Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG201100805-9A SG169382A1 (en) 2006-02-06 2007-02-05 Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products

Country Status (21)

Country Link
US (2) US8388958B2 (enExample)
EP (2) EP1981981B1 (enExample)
JP (1) JP5306828B2 (enExample)
KR (1) KR101429297B1 (enExample)
CN (1) CN101379192B (enExample)
AT (1) ATE514715T1 (enExample)
AU (1) AU2007213804B2 (enExample)
BR (1) BRPI0707480A8 (enExample)
CA (1) CA2638889C (enExample)
CY (1) CY1111884T1 (enExample)
DK (1) DK1981981T3 (enExample)
EA (1) EA015580B1 (enExample)
ES (1) ES2368864T3 (enExample)
IL (1) IL192879A (enExample)
MX (1) MX2008009833A (enExample)
PL (1) PL1981981T3 (enExample)
PT (1) PT1981981E (enExample)
SG (2) SG169383A1 (enExample)
SI (1) SI1981981T1 (enExample)
WO (1) WO2007090807A1 (enExample)
ZA (1) ZA200806559B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
IL198545A0 (en) * 2008-05-14 2011-07-31 Metheresis Translational Res Sa High affinity binding site of hgfr and methods for identification of antagonists thereof
EP2127683A1 (en) * 2008-05-29 2009-12-02 Metheresis Translational Research SA Anti-Met monoclonal antibody, fragments and derivatives thereof for use in tumor imaging, corresponding compositions and kits
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
KR101671378B1 (ko) * 2009-10-30 2016-11-01 삼성전자 주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
KR101748707B1 (ko) * 2009-11-27 2017-06-20 삼성전자주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트
WO2011110642A2 (en) 2010-03-10 2011-09-15 Genmab A/S Monoclonal antibodies against c-met
US9175084B2 (en) 2010-04-02 2015-11-03 Fujirebio Inc. Diagnostic marker for effect of anticancer agent
AU2011261161A1 (en) * 2010-06-01 2013-01-10 Ludwig Institute For Cancer Research Limited Antibodies directed to the unprocessed receptor tyrosine kinase c-Met
WO2012030842A2 (en) * 2010-09-03 2012-03-08 Academia Sinica Anti-c-met antibody and methods of use thereof
BR122014027420A2 (pt) 2010-11-03 2019-08-20 Argenx Bvba Anticorpos anti c-met
SI2500036T1 (sl) * 2011-03-18 2014-09-30 Metheresis Translational Research Sa Met inhibitorji za izboljĺ anje uäśinkovitosti obsevanja
US9201074B2 (en) 2011-09-20 2015-12-01 Eli Lilly And Company Anti-c-Met antibodies
WO2013064700A2 (en) 2011-11-03 2013-05-10 Argen-X B.V. Chimeric polypeptides and methods of use
MX2014005885A (es) 2011-11-21 2014-09-04 Genentech Inc Purificacion de anticuerpos anti-c-met.
WO2013079973A1 (en) * 2011-12-02 2013-06-06 Di Cara Danielle Marie Antibodies against hgf - receptor and uses
KR101910601B1 (ko) 2011-12-22 2018-10-23 삼성전자주식회사 면역원성이 제거된 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
CN103382223B (zh) * 2012-04-01 2015-06-10 上海益杰生物技术有限公司 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
JP6429771B2 (ja) * 2012-06-21 2018-11-28 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ｃ−Ｍｅｔに結合する抗原結合タンパク質
ITTO20130012A1 (it) 2013-01-09 2014-07-10 Metheresis Translational Res S A Nuovi frammenti anticorpali, relative composizioni ed usi
ES2748295T3 (es) 2014-09-16 2020-03-16 Symphogen As Anticuerpos anti-MET y composiciones
WO2016149116A1 (en) * 2015-03-13 2016-09-22 University Of Maryland, Baltimore Antibodies targeting s100b and methods of use
WO2016149265A1 (en) * 2015-03-16 2016-09-22 Kolltan Pharmaceuticals, Inc. Anti-met antibodies and methods of use thereof
IT201800000534A1 (it) * 2018-01-03 2019-07-03 Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici.
GB201611123D0 (en) * 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
MX420249B (es) 2016-09-29 2025-02-10 Mitsubishi Tanabe Pharma Corp Agentes de unión monoclonales de cmet, conjugados de fármaco de los mismos y usos de los mismos.
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
CN106872695B (zh) * 2017-01-20 2019-06-11 中山大学 一种h7亚型禽流感病毒血凝素抗体间接elisa检测试剂盒
IT201800000535A1 (it) 2018-01-03 2019-07-03 Procedimenti per la cura del cancro.
IT201800003875A1 (it) 2018-03-22 2019-09-22 Metis Prec Medicine Sb S R L Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi
US12060427B2 (en) * 2018-03-28 2024-08-13 Mitsubishi Tanabe Pharma Corporat Drug conjugates of cMET monoclonal binding agents, and uses thereof
IT201800009282A1 (it) 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
JP7750828B2 (ja) 2019-09-16 2025-10-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫ｐｅｔ撮像のための放射標識されたｍｅｔ結合タンパク質
TW202448953A (zh) 2023-06-01 2024-12-16 法商皮爾法伯製藥公司 用於腫瘤及轉移之治療的基於沉默抗體的抗met建構物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US6814962B1 (en) 1994-06-02 2004-11-09 Aventis Pharma S.A. Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET

Also Published As

Publication number Publication date
CN101379192B (zh) 2013-07-31
IL192879A0 (en) 2009-02-11
IL192879A (en) 2014-02-27
BRPI0707480A8 (pt) 2022-11-08
CA2638889A1 (en) 2007-08-16
KR20090013745A (ko) 2009-02-05
EP1981981A1 (en) 2008-10-22
PL1981981T3 (pl) 2011-11-30
AU2007213804A1 (en) 2007-08-16
US8388958B2 (en) 2013-03-05
KR101429297B1 (ko) 2014-08-12
US8729043B2 (en) 2014-05-20
WO2007090807A1 (en) 2007-08-16
US20120134996A1 (en) 2012-05-31
ES2368864T3 (es) 2011-11-23
CY1111884T1 (el) 2015-11-04
AU2007213804B2 (en) 2012-12-13
MX2008009833A (es) 2008-10-23
US20090285807A1 (en) 2009-11-19
SG169382A1 (en) 2011-03-30
EP2192188A1 (en) 2010-06-02
JP5306828B2 (ja) 2013-10-02
PT1981981E (pt) 2011-10-04
ZA200806559B (en) 2012-12-27
JP2009526010A (ja) 2009-07-16
CN101379192A (zh) 2009-03-04
ATE514715T1 (de) 2011-07-15
CA2638889C (en) 2015-06-02
AU2007213804A8 (en) 2008-08-28
BRPI0707480A2 (pt) 2011-05-03
DK1981981T3 (da) 2011-09-26
EA200870234A1 (ru) 2009-02-27
SI1981981T1 (sl) 2012-01-31
EA015580B1 (ru) 2011-10-31
EP1981981B1 (en) 2011-06-29

Similar Documents

Publication Publication Date Title
SG169382A1 (en) Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
MX2012004258A (es) Inhibidores de la tirosina quinasa de bruton.
ZA200702973B (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
PH12014500122A1 (en) Inhibitors of bruton's tyrosine kinase
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
MX2010006823A (es) Metodos para el tratamiento de la gota.
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
NZ607710A (en) 4-1bb binding molecules
EA200970738A1 (ru) Ингибиторы активности akt
IL226717A (en) Isolated nucleic acids encoded by anti-beta human antibodies 7
ES2531093T3 (es) Procedimiento de preparación de halogenuros de N-alquil-naltrexona
WO2008034142A3 (en) Synthesis, methods of using, and compositions of cycloalkylmethylamines
MX2009009816A (es) Anticuerpos monoclonales para el tratamiento del cancer.
MY159491A (en) Disubstituted phthalazine hedgehog pathway antagonists
TN2011000166A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
WO2008061020A3 (en) Methods of treating, diagnosing or detecting cancer
NZ597531A (en) Inhibition of tumor metastasis using bv8- or g-csf-antagonists
TNSN08401A1 (en) Methods of treating diagnosing or detecting cancer
UA99601C2 (ru) Применение антитела к cd151 для лечения первичных опухолей
WO2009018226A3 (en) Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (cd49e)
WO2007107748A3 (en) Inhibition of tumour growth
ATE458487T1 (de) Tumorbehandlung mit gliotoxin-derivaten
DK1869185T3 (da) Konjugat med P21-protein til kræftbehandling
WO2007110210A3 (en) Angiomotin sirna molecules and uses thereof
GB0624687D0 (en) Treatment of cachexia